Nabriva Therapeutics shares are trading higher after the company announced it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective on September 16, 2022.(Benzinga)
Nabriva Therapeutics Completes Patient Enrollment In Phase 1 Trial Of XENLETA In Adult Patients With Cystic Fibrosis
Nabriva
Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in
the commercialization and development of innovative anti-infective
agents to treat serious infections, announced the completion of patient
enrollment in its Phase 1 clinical trial to assess the safety and
pharmacokinetics of oral and intravenous XENLETA® (lefamulin) in adult
patients with cystic fibrosis (CF).
"We are happy to announce enrollment has been completed in this important study to evaluate the potential of XENLETA in the management of bacterial infections in patients with cystic fibrosis," said Christine Guico-Pabia, M.D., MBA, MPH, Nabriva's Chief Medical Officer. "XENLETA has the potential to provide a well-tolerated oral and intravenous anti-MRSA treatment option with a novel mechanism for this difficult to treat patient population."
Dr. Guico-Pabia added, "With enrollment now complete, we expect to report topline data in the first quarter of 2023. We look forward to sharing the results of this study with the medical community. Thank you to the investigators and patients who participated in this important trial, as well as the Cystic Fibrosis Foundation for their support."
About the Trial
The Phase 1 trial is an open-label, randomized, crossover study to assess the safety and pharmacokinetics following single doses of oral and intravenous XENLETA in adult patients with cystic fibrosis.
More information can be found at ClinicalTrials.gov -NCT05225805.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
No comments:
Post a Comment